NCT03980912 is a clinical trial of LiverFASt in NAFLD, sponsored by Fibronostics USA, Inc.

Who is sponsoring NCT03980912?

NCT03980912 is sponsored by Fibronostics USA, Inc.

What drugs are being tested in NCT03980912?

Interventions in NCT03980912: LiverFASt.

What condition does NCT03980912 study?

NCT03980912 studies NAFLD, NASH.

Is NCT03980912 still recruiting?

NCT03980912 is currently withdrawn. Last updated 3 February 2021.

Last reviewed 2021-02-03 · How we verify

NCT03980912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

Withdrawn Last updated 3 February 2021

What this trial tests

trial testing LiverFASt in NAFLD. Withdrawn.

Timeline

1 September 2019

Primary endpoint
1 September 2020

1 November 2020

Quick facts

Lead sponsor	Fibronostics USA, Inc
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	1 September 2019
Primary completion	1 September 2020
Estimated completion	1 November 2020
Sites	1 location across United States

Drugs / interventions tested

LiverFASt

Conditions studied

NAFLD — all drugs for NAFLD →
NASH — all drugs for NASH →

Sponsor

Fibronostics USA, Inc

Who can join

Adults 18 to 80, any sex, with NAFLD or NASH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to assess the diagnostic performance of the LiverFASt Test for assessing fibrosis staging scores compared to the assessment of liver tissue pathology from liver biopsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NAFLD

Currently open trials in the same condition.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting

Other Fibronostics USA, Inc trials

Trials by the same sponsor.

NCT04579874 — Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03980912 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fibronostics USA, Inc
Last refreshed: 3 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing